FY2026 Earnings Estimate for CRSP Issued By Chardan Capital
CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Stock analysts at Chardan Capital issued their FY2026 earnings per share estimates for CRISPR Therapeutics in a report issued on Wednesday, May 7th. Chardan Capital analyst Y. Livshits expects that the company will earn ($3.97) per share for the year. Chardan Capital has a “Buy” rating and […]
CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) – Stock analysts at Chardan Capital issued their FY2026 earnings per share estimates for CRISPR Therapeutics in a report issued on Wednesday, May 7th. Chardan Capital analyst Y. Livshits expects that the company will earn ($3.97) per share for the year. Chardan Capital has a “Buy” rating and […]
